New CEO at the Spondylitis Association of America (SAA)

Cassie Shafer joined the Spondylitis Association of America (SAA) as the new CEO in late September 2017. Cassie brings with her a unique set of skills that she acquired over her many years of experience with national US healthcare nonprofits, where she has distinguished herself as a nationally recognized staff leader. Over the past 30 years Cassie has held executive and management positions in health care with organizations such as American Heart Association, American Lung Association, National Kidney Foundation and most recently the American Diabetes Association. Her focus has been on setting vision, driving performance management through best practices and benchmarks, revenue forecasting and budget optimization, developing program strategy, coaching staff and volunteers, and community organization and board development.

“I am so excited for this opportunity to join the SAA,” Shafer said. “I look forward to working with our Board of Directors, Medical Advisory Board and the staff to take the SAA to the next level in terms of patient support, fundraising and research of the disease.”

2018 marks the 35th anniversary of SAA. Many great and notable accomplishments have been made over this period of time. Cassie looks forward to leading SAA in the continued fight to improve the lives of patients and families who have experienced the devastating consequences of ankylosing spondylitis and related diseases. She is also excited to expand support for essential research projects, launch an e-advocacy platform, develop new programs to reach Primary Care Physicians (and other key healthcare providers) to improve early identification of axSpA among patients with chronic back pain, and create a more robust social media exchange around #backpainmatters.

SAA Website

Other NEWS

Intimacy and AS

Michael Mallinson has lived with AS for over 35 years. He developed this content as a consultant to Novartis Ph

Read More
UCB’s CIMZIA© approved for potential use in women with AS during breastfeeding and pregnancy

The European Medicines Agency (EMA) has approved the label change for UCB's CIMZIA© (certolizumab pegol), making i

Read More